Lianbio
A biopharmaceutical company that acted as a bridge for Western drugmakers wanting to enter China, in-licensing experimental medicines from partners like Pfizer and BridgeBio and running their clinical trials in Asia across oncology, heart disease, and eye care. Founded in 2019 by the American investment firm Perceptive Advisors, it took its name from the Chinese character "lián," meaning "to link" or "to connect" — a nod to its mission of linking global innovation with the Chinese market. In 2024 it wound down its drug business and later merged into LianMedical, a medical-device company starting with heart-failure treatments.
Sponsored ADR — Delisted from Nasdaq, shut down operations in 2024
2.05 Costs Associated with Exit or Disposal Activities · 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · 7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 1.02 Termination of a Material Definitive Agreement
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
8.01 Other Events · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 1.02 Termination of a Material Definitive Agreement · 2.01 Completion of Acquisition or Disposition of Assets · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits